Aethlon Medical(US:AEMD)2024-11-14 00:58Financial Data and Key Metrics Changes - As of September 30, 2024, Aethlon Medical held a cash balance of approximately $6.9 million [22] - For the fiscal quarter ended September 30, 2024, consolidated operating expenses were approximately $2.9 million, a decrease from $3.2 million in the same period of 2023, representing a 9% reduction [22][25] - The net loss decreased to approximately $2.8 million in the fiscal quarter ended September 30, 2024, from approximately $3 million in the same quarter of 2023 [25] Business Line Data and Key Metrics Changes - The company advanced its oncology trial efforts in Australia, enrolling the first two patients in a clinical trial [8][9] - Aethlon received ethics committee approval for a similar trial in India, which will also focus on safety and feasibility [13] Market Data and Key Metrics Changes - The company is exploring opportunities to expand the use of the Hemopurifier for life-threatening viral infections, showing effectiveness against various viruses [19] Company Strategy and Development Direction - Aethlon Medical is focused on the research and clinical development of its Hemopurifier, targeting oncology and viral infections [6][19] - The company aims to streamline operations and reduce expenses while advancing its oncology program [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the progress of the oncology program and the potential for shareholder rewards [7] - The company is optimistic about the upcoming milestones in its clinical trials and the expected benefits from the Australian tax credit program [37] Other Important Information - The Hemopurifier is designed to bind and remove harmful exosomes and viruses, with potential applications in oncology and organ transplantation [6] - The company is awaiting full ethics board approval from a third Australian hospital, which is expected to expedite patient enrollment [10] Q&A Session Summary Question: Are the first two patients enrolled in the study representative of different solid tumor types? - Yes, both patients have different tumor types as described in the inclusion criteria [28][29] Question: Is the company confident about receiving ethics committee approval for the third site in Australia? - Yes, there is high confidence due to prior ethics approval from another site and ongoing training for the staff [30][31] Question: Why are there two separate trials in India and Australia with the same safety endpoint? - The decision was made to keep the patient populations distinct due to genetic and comorbidity differences [40] Question: When can the company expect to conclude enrollment and data from the trial in Australia? - The first data on safety is expected in January, with further data on extracellular vesicles and T-cell activity to follow in the summer of next year [44][45]